Daewoong Pharma published its 2026 Sustainability Report disclosing ESG performance and plans for the year 2025.
The report complies with international standards such as GRI 2021, ISSB, SASB, and TCFD, covering environmental, social, and governance non-financial information.
This filing is a routine ESG disclosure that does not involve any capital changes, share buybacks, or dividend adjustments directly affecting shareholder value.
[AI Summary]Daewoong Pharma sustainability report is a regular ESG disclosure transparently presenting the company environmental, social, and governance activities without direct financial impact or capital structure changes. It contributes to long-term ESG risk management and corporate reputation rather than short-term stock price movements.
KOSPI Filing Information
Matters Related to Sustainability Management Report, etc. (Voluntary Disclosure)